ES2080334T3 - Antagonistas de leucotrieno b4. - Google Patents

Antagonistas de leucotrieno b4.

Info

Publication number
ES2080334T3
ES2080334T3 ES91916271T ES91916271T ES2080334T3 ES 2080334 T3 ES2080334 T3 ES 2080334T3 ES 91916271 T ES91916271 T ES 91916271T ES 91916271 T ES91916271 T ES 91916271T ES 2080334 T3 ES2080334 T3 ES 2080334T3
Authority
ES
Spain
Prior art keywords
alkyl
antagonists
compounds
formula
image
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91916271T
Other languages
English (en)
Inventor
Stevan Wakefield Djuric
Stephen Hermann Docter
Stella Siu-Tzyy Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of ES2080334T3 publication Critical patent/ES2080334T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Spray-Type Burners (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

EL INVENTO SE REFIERE A COMPUESTOS DE LA FORMULA (I) Y LOS ESTEROISOMEROS Y SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, EN DONDE R ES ALQUILO, ALQUENILO, ALQUINILO, O CICLOALQUILALQUILO; R1 ES ALQUILO; R2 ES HIDROGENO O ALQUILO; R6 ES ALQUILO; N ES DE 1 A 5 ; P ES DE 0 A 6; X ES 0 O 2; Y R4 Y R5 SON INDEPENDIENTEMENTE HIDROGENO O ALQUILO O JUNTO CON N FORMAN UNA CICLOALQUILAMINA. LOS COMPUESTOS DE FORMULA (I) SON ANTAGONISTAS DE LEUCOTRIENO B4 Y SON UTILES COMO AGENTES ANTI-INFLAMATORIOS Y EN EL TRATAMIENTO DE LAS CONDICIONES DE ENFERMEDADES PRODUCIDAS POR LTB4.
ES91916271T 1990-06-28 1991-06-27 Antagonistas de leucotrieno b4. Expired - Lifetime ES2080334T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/545,430 US5124350A (en) 1990-06-28 1990-06-28 Leukotriene b4 antagonists

Publications (1)

Publication Number Publication Date
ES2080334T3 true ES2080334T3 (es) 1996-02-01

Family

ID=24176217

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91916271T Expired - Lifetime ES2080334T3 (es) 1990-06-28 1991-06-27 Antagonistas de leucotrieno b4.

Country Status (13)

Country Link
US (4) US5124350A (es)
EP (1) EP0593478B1 (es)
JP (1) JP2942630B2 (es)
AT (1) ATE131165T1 (es)
AU (1) AU8528291A (es)
CA (1) CA2081766C (es)
DE (1) DE69115297T2 (es)
DK (1) DK0593478T3 (es)
ES (1) ES2080334T3 (es)
GR (1) GR3018322T3 (es)
IE (1) IE62680B1 (es)
PT (1) PT98140B (es)
WO (1) WO1992000011A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124350A (en) * 1990-06-28 1992-06-23 G. D. Searle & Co. Leukotriene b4 antagonists
US5451700A (en) * 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
US5488160A (en) * 1991-06-11 1996-01-30 Ciba-Geigy Corporation Amidino compounds, their manufacture and method of treatment
US5273999A (en) * 1991-09-10 1993-12-28 Hoffmann-La Roche Inc. Carboxylic acid leukotriene B4 antagonists
US5252599A (en) * 1992-08-27 1993-10-12 Merck Frosst Canada, Inc. Heteroarylnaphthalene hydroxy acids as inhibitors of leukotriene biosynthesis
US5455274A (en) * 1992-12-09 1995-10-03 Ciba-Geigy Corporation Hydroxyamidine derivatives
US5324743A (en) * 1992-12-10 1994-06-28 Eli Lilly And Company Leukotriene B4 antagonists
US5516917A (en) * 1994-06-08 1996-05-14 G. D. Searle & Co. Leukotriene B4 antagonists
CN1160399A (zh) * 1994-10-13 1997-09-24 美国辉瑞有限公司 苯并吡喃和苯并稠合化合物、其制备方法和它们作为白三烯b4(ltb4)拮抗剂的用途
MX9702734A (es) * 1994-10-13 1997-06-28 Pfizer Benzopirano y compuestos benzocondensados, su preparacion y su uso como antagonistas de leucotrieno b4 (ltb4).
US6342510B1 (en) 1995-06-12 2002-01-29 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
ES2243978T3 (es) * 1996-02-13 2005-12-01 G.D. SEARLE & CO. Composiciones que comprenden un inhibidor de la ciclooxigenasa-2 y un antagonista del receptor de leucotrieno b4.
US6403684B1 (en) * 1998-12-16 2002-06-11 General Electric Company Polyetherimide resin/polyester resin blends having improved visual clarity
JP2004513090A (ja) 2000-09-27 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病及び脂質異常症の治療のためのベンゾピランカルボン酸誘導体
WO2002060434A2 (en) 2000-10-31 2002-08-08 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
EP1773396A1 (en) * 2004-07-22 2007-04-18 Pharmacia Corporation Compositions for treatment of inflammation and pain using a combination of a cox-2 selective inhibitor and a ltb4 receptor antagonist
US7572600B2 (en) * 2004-08-04 2009-08-11 Chemocentryx, Inc. Enzymatic activities in chemokine-mediated inflammation
CN101193862B (zh) * 2005-04-13 2013-08-21 阿斯特克斯治疗有限公司 羟基苯甲酰胺衍生物和其作为hsp90抑制剂的用途
US7754725B2 (en) * 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US8916552B2 (en) * 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
US8883790B2 (en) * 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
JP5721949B2 (ja) * 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
JP5410285B2 (ja) * 2006-10-12 2014-02-05 アステックス、セラピューティックス、リミテッド 医薬化合物
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
EP3268085A4 (en) 2015-03-13 2018-10-31 The Board of Trustees of The Leland Stanford Junior University Ltb4 inhibition to prevent and treat human lymphedema

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1384530A (en) * 1971-07-29 1975-02-19 Fisons Ltd Chromone derivatives
ATE14579T1 (de) * 1979-03-20 1985-08-15 Fisons Plc Pharmazeutische heterocyclische verbindungen, verfahren zu ihrer herstellung und sie enthaltende zusammensetzungen.
DE3068213D1 (en) * 1979-09-05 1984-07-19 Glaxo Group Ltd Phenol derivatives, processes for their preparation and pharmaceutical compositions containing them
DE3275295D1 (en) * 1981-11-12 1987-03-05 Fisons Plc Anti-srs-a carboxylic acid derivatives, processes for their production, and pharmaceutical formulation containing them
ZA844519B (en) * 1983-06-24 1985-02-27 Hoffmann La Roche Dihydrobenzopyran derivatives
US4778903A (en) * 1983-12-12 1988-10-18 G. D. Searle & Co. Substituted dihydrobenzopyrans
US4665203A (en) * 1983-08-08 1987-05-12 G. D. Searle & Co. Substituted dihydrobenzopyrans useful as leukotriene D4 inhibitors
US4565882A (en) * 1984-01-06 1986-01-21 G. D. Searle & Co. Substituted dihydrobenzopyran-2-carboxylates
US4546194A (en) * 1984-05-29 1985-10-08 G. D. Searle & Co. Substituted chromanon-2-yl alkanols and derivatives thereof
US4889871A (en) * 1987-05-29 1989-12-26 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives
EP0336068A1 (en) * 1988-02-11 1989-10-11 F. Hoffmann-La Roche Ag Phenoxyalkoxy-3,4-dihydro-2H-1-benzopyran derivatives
US5124350A (en) * 1990-06-28 1992-06-23 G. D. Searle & Co. Leukotriene b4 antagonists
DE4206523A1 (de) * 1992-03-02 1993-09-09 Vdo Schindling Vorrichtung zur verstellung einer drosselklappe

Also Published As

Publication number Publication date
EP0593478B1 (en) 1995-12-06
WO1992000011A2 (en) 1992-01-09
DK0593478T3 (da) 1996-01-08
GR3018322T3 (en) 1996-03-31
IE62680B1 (en) 1995-02-22
CA2081766A1 (en) 1991-12-29
US5124350A (en) 1992-06-23
CA2081766C (en) 2002-10-08
AU8528291A (en) 1992-01-23
IE912255A1 (en) 1992-01-01
US5532383A (en) 1996-07-02
US5310951A (en) 1994-05-10
PT98140B (pt) 1998-12-31
JP2942630B2 (ja) 1999-08-30
DE69115297D1 (de) 1996-01-18
US5439937A (en) 1995-08-08
EP0593478A1 (en) 1994-04-27
DE69115297T2 (de) 1996-06-13
PT98140A (pt) 1993-09-30
JPH05507720A (ja) 1993-11-04
ATE131165T1 (de) 1995-12-15
WO1992000011A3 (en) 1992-02-06

Similar Documents

Publication Publication Date Title
DE69115297D1 (de) Leukotrien-b4-antagonisten.
ES2069295T3 (es) Acidos dihidrobenzopiran-2-carboxilicos substituidos con alcoxi y derivados de los mismos.
SE8201854L (sv) N-substituerade amino-aminosyror
ZA793150B (en) 2-(2-alkoxyethyl)-2'-hydroxy-6,7-benzomorphanes,processes for their preparation,and pharmaceutical compositions thereof
ES2046641T3 (es) Composicion antitumoral.
ES2055235T3 (es) Composicion anti-inflamatoria y/o antialergica que comprende derivados de glutation.
EG16546A (en) Therapeutic agents
ES2062792T3 (es) Acidos dihidrobenzopiran-2-carboxilicos alcoxi-sustituidos y derivados de los mismos.
GB8921792D0 (en) New compositions of matter
DE69001004D1 (de) Zusammensetzung gegen leberkrankheiten.
TW225989B (es)
ES488387A1 (es) Procedimiento de preparacion de derivados condensados de pi-rrolidina
IE873182L (en) Triazaspirodecanylmethylindolone derivatives
TNSN86099A1 (fr) Nouveaux benzamides, leur procede de preparation et leur application dans le domaine therapeutique
ES2152009T3 (es) Nuevos derivados de glicilanilidas, su preparacion y su aplicacion en terapeutica.
ATE81465T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 593478

Country of ref document: ES